Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.66
- Piotroski Score 2.00
- Grade Sector Perform
- Symbol (EDIT)
- Company Editas Medicine, Inc.
- Price $2.38
- Changes Percentage (-1.45%)
- Change -$0.04
- Day Low $2.30
- Day High $2.47
- Year High $11.69
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $12.00
- High Stock Price Target $35.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.07
- Trailing P/E Ratio -2.56
- Forward P/E Ratio -2.56
- P/E Growth -2.56
- Net Income $-153,219,000
Income Statement
Quarterly
Annual
Latest News of EDIT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The 50 Best Black Friday Deals So Far, According To Our Deals Editors
The holiday shopping season is in full swing, with early Black Friday deals already available. Standout discounts include 25% off Away luggage, DreamCloud mattresses from $419, and 25% off at Brooklin...
By Forbes | 1 day ago -
Act now for $7,500 EV tax credit: There's 'real risk' Trump will axe funding in 2025, lawyer says
There is a risk of losing the Biden-era EV tax credit of up to $7,500 due to potential removal by Trump and Republicans. Experts advise consumers to consider purchasing an electric vehicle before 2025...
By NBC News | 1 day ago -
Ofgem consulting on new fund to expedite transmission projects
Ofgem in the UK plans to introduce the Advanced Procurement Mechanism (APM) to speed up the transition to net zero by pre-purchasing vital energy transmission equipment....
By Yahoo! Finance | 1 day ago
